Human longevity assurance protein, its coding sequence and their use
    3.
    发明授权
    Human longevity assurance protein, its coding sequence and their use 失效
    人类长寿保证蛋白,其编码序列及其用途

    公开(公告)号:US07037683B2

    公开(公告)日:2006-05-02

    申请号:US10389222

    申请日:2003-03-14

    IPC分类号: A61K38/17 C07K14/47

    CPC分类号: C07K14/435 A61K38/00

    摘要: The present invention relates to a novel human longevity assurance protein, the polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. The present invention also relates to a method of applying the polypeptide for the treatment of various kinds of disease, such as cancer. Further, the present invention relates to the antagonist of the polypeptide and therapeutic use of the same. In addition, the present invention includes the use of the polynucleotide encoding the human longevity assurance protein.

    摘要翻译: 本发明涉及新的人类寿命保证蛋白,编码多肽的多核苷酸和通过重组方法制备多肽的方法。 本发明还涉及应用该多肽治疗各种疾病如癌症的方法。 此外,本发明涉及多肽的拮抗剂及其治疗用途。 此外,本发明包括编码人类寿命保证蛋白质的多核苷酸的用途。

    Anti-EFGRv3 monoclonal antibody
    4.
    发明授权
    Anti-EFGRv3 monoclonal antibody 有权
    抗EFGRv3单克隆抗体

    公开(公告)号:US08506963B2

    公开(公告)日:2013-08-13

    申请号:US13497763

    申请日:2009-09-22

    IPC分类号: A61K39/395 C12P19/34

    摘要: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.

    摘要翻译: 本发明提供特异性结合蛋白及其用途。 特别地,本发明提供了可以有效结合表皮生长因子受体变体III型(EGFRvIII)或可部分结合细胞中过表达的表皮生长因子受体(EGFR)但不与EGFR正常结合的单克隆抗体, 在细胞中表达。 此外,本发明所述抗体对表达EGFRvIII的肿瘤细胞系具有明显的治疗作用。 本发明还提供了制备所述单克隆抗体的方法和包含所述单克隆抗体的药物组合物。

    SPECIFIC BINDING PROTEINS AND USES THEREOF
    5.
    发明申请
    SPECIFIC BINDING PROTEINS AND USES THEREOF 有权
    特异性结合蛋白及其用途

    公开(公告)号:US20130039920A1

    公开(公告)日:2013-02-14

    申请号:US13497763

    申请日:2009-09-22

    摘要: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.

    摘要翻译: 本发明提供特异性结合蛋白及其用途。 特别地,本发明提供了可以有效结合表皮生长因子受体变体III型(EGFRvIII)或可部分结合细胞中过表达的表皮生长因子受体(EGFR)但不与EGFR正常结合的单克隆抗体, 在细胞中表达。 此外,本发明所述抗体对表达EGFRvIII的肿瘤细胞系具有明显的治疗作用。 本发明还提供了制备所述单克隆抗体的方法和包含所述单克隆抗体的药物组合物。

    Composition and method for preparing alginate nanocapsules
    9.
    发明授权
    Composition and method for preparing alginate nanocapsules 有权
    制备藻酸盐纳米胶囊的组合物和方法

    公开(公告)号:US08449919B2

    公开(公告)日:2013-05-28

    申请号:US11368743

    申请日:2006-03-06

    IPC分类号: A61K9/50 B29C39/10

    CPC分类号: A61K9/5161 A61K9/5192

    摘要: The present invention discloses a method for preparing alginate nanocapsules, including the steps of: (a) forming a water-in-oil emulsion including an alginate in water, an oil, and at least one nonionic surfactant; and (b) separating the aqueous phase and oil phase to obtain the semisolid form alginate nanocapsules; and (c) by ionically crosslinking the alginate with calcium ions to obtain a colloidal form of calcium alginate nanocapsules for drug delivery.

    摘要翻译: 本发明公开了一种藻酸盐纳米胶囊的制备方法,包括以下步骤:(a)在水,油和至少一种非离子表面活性剂中形成包含藻酸盐的油包水乳液; 和(b)分离水相和油相以获得藻酸盐半固体形式的纳米胶囊; 和(c)通过藻酸盐与钙离子离子交联以获得用于药物递送的胶体形式的藻酸钙纳米胶囊。